ScinoPharm, Raffles PharmaTech Partner

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech have formed a collaboration to manufacture celecoxib, a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). Raffles will be responsible for R&D, and ScinoPharm (Changshu) will be responsible fore manufacturing. After the product launch, both sides will share the profits. The drug master file (DMF) is expected to be submitted in 2016, and products will be available in the United States by 2018.

Raffles PharmaTech is located in Huizhou, Guangdong, China, and manufactures organic macromolecule catalysts, pharmaceutical intermediates, and APIs.

ScinoPharm Taiwan, Ltd. is a process R&D and API manufacturing service provider with research and manufacturing facilities in Taiwan and China, ScinoPharm offers a custom synthesis for early phase pharmaceutical activities for brand companies as well as APIs for the generic industry. The company also is pursuing a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of sterile oncological injectable formulations.

Source: ScinoPharm

Leave a Reply

Your email address will not be published. Required fields are marked *